Armata Pharmaceuticals Inc
armatapharma.comArmata Pharmaceuticals Inc (NASDAQ: ARMP) is a clinical-stage biopharmaceutical company focused on developing bacteriophage-based therapeutics targeting antibiotic-resistant bacterial infections. The company has no commercialized products as of the FY2025 10-K filed March 25, 2026, and generates no product revenue. Armata is developing candidates targeting infections including Staphylococcus aureus bacteremia, prosthetic joint infections, and wound infections, areas where drug-resistant strains have outpaced existing treatments such as vancomycin and daptomycin. The company operates a Los Angeles production facility maintained under current Good Manufacturing Practices. Armata relies on third-party contract research organizations and manufacturers for portions of its development work. Its capital structure includes a convertible loan and term debt as of December 31, 2025, with no dividend payments. IP protection relies on patents, trade secrets, and data exclusivity tied to biologics regulatory pathways, including potential orphan drug and pediatric use extensions.
Products & Services
Bacteriophage-based therapeutic product candidates targeting antibiotic-resistant bacterial infections, specifically Staphylococcus aureus bacteremia, prosthetic joint infections, and wound infections. No products are FDA-approved or commercialized as of the FY2025 10-K filing.
Revenue Model
No product revenue as of FY2025. The company is pre-commercialization and funds operations through equity and debt financing, including a convertible loan and term debt visible on the December 31, 2025 balance sheet. Future revenue, if any, would depend on regulatory approval and third-party payor reimbursement from Medicare, Medicaid, private insurers, and managed-care plans.
Customers & Markets
Target end markets include hospital and institutional settings treating patients with S. aureus bacteremia and prosthetic joint infections. S. aureus PJI-related revision surgeries in the United States and EU Five were approximately 70,000 in 2020, projected to reach 144,000 by 2040. The United States accounted for 61% of PJI-related revision surgeries in 2020, estimated at $150,000 each. No commercial customers exist as of the FY2025 filing.
Geographic Exposure
Primary operations in Los Angeles, California. Regulatory focus is on FDA approval in the United States. The filing notes subject to foreign regulatory requirements for any future international clinical trials or marketing, but no international commercial operations exist as of the FY2025 10-K.
Financial Snapshot
Loading...
